May 11, 2020   Real world versus trials: How DME patients may fare differently Patients with DME being treated in a real-world practice may receive fewer anti-VEGF injections and their visual gains may be worse compared with patients in randomized clinical trials, suggest researchers. Find out ADVERTISEMENT   Screening DR + tele-ophthalmology AI: Less expensive than human assessment? Adding AI technology using deep-learning systems in a semi-automated model has been shown to be equally effective as the assessment performed by trained human graders for detecting diabetic retinopathy. Find out ADVERTISEMENT Determining risk of ocular damage from chronic intravitreal injections Intravitreal injections used to treat a variety of ocular diseases may themselves contribute to progressive visual loss with chronic administration over years, according to researchers. Learn more   RELATED ARTICLES Managing patient visits amid the COVID-19 pandemic Ranibizumab reported safe for bilateral macular degeneration Autonomous diagnostics for DR: ‘Jump-start’ to AI ophthalmology DARPin molecule reducing wet AMD treatment burden for patients